11.13.13
European regulators have given their blessing to an ultra-low power system from Toumaz Ltd. that wirelessly monitors patients' vital signs.
CE Mark approval of the company's SensiumVitals system follows the product's U.S. Food and Drug Administration 510(k) clearance in July 2011. The CE Mark allows Toumaz to sell the SensiumVitals system throughout the European Union.
The company also has secured the first United Kingdom pilot deployment of SensiumVitals with Spire Healthcare (Spire), a leading British provider of private healthcare. The pilot will start in a Spire Healthcare hospital in early 2014, Toumaz executives said. Spire operates 38 hospitals throughout the United Kingdom. A similar pilot, conducted earlier this year in the med-surgical unit at St. John’s Health Center in Santa Monica, Calif., provided clear evidence of both the clinical and economic benefits of the system.
Besides its CE Mark approval, Toumaz has worked out a new distribution agreement with NantHealth for SensiumVitals in North America, including its first commercial order and confirmation of its first pilot deployment in an A&E department at Hurley Medical Center in Flint, Mich.
”Results from the SensiumVitals pilot in North America have provided clear evidence that the system can shorten hospital stays and reduce healthcare costs. We are confident that similar results will be achieved in the UK and the rest of Europe”, said Anthony Sethill, CEO of Toumaz.
CE Mark approval of the company's SensiumVitals system follows the product's U.S. Food and Drug Administration 510(k) clearance in July 2011. The CE Mark allows Toumaz to sell the SensiumVitals system throughout the European Union.
The company also has secured the first United Kingdom pilot deployment of SensiumVitals with Spire Healthcare (Spire), a leading British provider of private healthcare. The pilot will start in a Spire Healthcare hospital in early 2014, Toumaz executives said. Spire operates 38 hospitals throughout the United Kingdom. A similar pilot, conducted earlier this year in the med-surgical unit at St. John’s Health Center in Santa Monica, Calif., provided clear evidence of both the clinical and economic benefits of the system.
Besides its CE Mark approval, Toumaz has worked out a new distribution agreement with NantHealth for SensiumVitals in North America, including its first commercial order and confirmation of its first pilot deployment in an A&E department at Hurley Medical Center in Flint, Mich.
”Results from the SensiumVitals pilot in North America have provided clear evidence that the system can shorten hospital stays and reduce healthcare costs. We are confident that similar results will be achieved in the UK and the rest of Europe”, said Anthony Sethill, CEO of Toumaz.